Ivemend (Fosaprepitant)

Fosaprepitant works by selectively blocking neurokinin‑1 (NK1) receptors in the brainstem’s vomiting centre. This inhibition prevents substance P, a neuropeptide that triggers emesis, from activating the receptor, thereby reducing the signalling cascade that leads to chemotherapy‑induced nausea and vomiting.

The dosing of Ivemend is determined by the prescribing clinician based on the chemotherapy protocol and patient characteristics. Typically, the drug is administered as an intravenous infusion shortly before the start of chemotherapy, but the exact amount and infusion rate are set by the treating physician.

The safety of fosaprepitant in pregnancy and lactation has not been established, and the product carries an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and a healthcare professional should be consulted.

To order Ivemend, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain where applicable) and any necessary import documentation.

The primary alternative to fosaprepitant is oral aprepitant, another NK1 receptor antagonist. Fosaprepitant offers a rapid intravenous route, which can be advantageous when oral administration is not feasible or when a quick onset is desired. Both agents share the same mechanism, but fosaprepitant avoids issues related to gastrointestinal absorption and may be preferred in patients with severe nausea.

Ivemend should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Maintaining the cold‑chain during transport and storage helps preserve drug stability and efficacy.

Ivemend is administered as an intravenous infusion. The recommended practice is to dilute the 150 mg/100 mL solution in an appropriate compatible IV fluid and infuse it over a short period, usually immediately before the chemotherapy infusion. Administration should be performed by qualified healthcare personnel following institutional protocols.

Serious adverse reactions include hypersensitivity events such as rash, urticaria, or anaphylaxis, as well as significant elevations in liver enzymes (ALT/AST) that may indicate hepatic injury. Rarely, cardiac arrhythmias have been reported. Patients should be monitored for these signs, and treatment should be discontinued if severe reactions occur.

Ivemend is contraindicated in individuals with known hypersensitivity to fosaprepitant or any component of the formulation. Caution is advised in patients with severe hepatic impairment, as drug clearance may be affected. Pregnant or breastfeeding women should avoid use unless the potential benefit outweighs the risk, and the decision should be made by a qualified clinician.